- Exhibit & Support
- Hotel & Travel
The pathophysiology of diabetes is more complex than we thought, and it demands an evolved understanding. We’ve gone from an “ominous octet” of dysfunctional organ systems to the “egregious eleven,” with interplay among type 1, type 1.5, and type 2 diabetes. This means metformin alone cannot always achieve glycemic control for many patients. Clinicians initiating a second-line therapy must choose from several treatment options, including insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium–glucose cotransporter 2 inhibitors. Attend this session to hear experts discuss unique treatment plans for patients with diabetes and learn how to identify the most appropriate adjunct therapies to control patients’ A1C and improve cardiovascular health.
At the completion of this knowledge-based activity, participants will be able to: